Unraveling the Complexity of Dry Eye: A Deep Dive into Advanced Treatment Strategies
Dry eye and ocular surface disease: A persistent challenge for clinicians. As we navigate an aging patient population with an increasing prevalence of systemic comorbidities, the management of these conditions becomes even more intricate. To shed light on the evolving landscape of ophthalmology, we reached out to renowned experts in the field. This insightful Q&A delves into the strategies and technologies shaping the future of dry eye treatment.
Leading the Discussion:
- Dr. Christopher E. Starr, Associate Professor of Ophthalmology, Director of Refractive Surgery Service, and Director of Ophthalmic Education at Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY.
- Dr. William Trattler, Refractive, Corneal, and Cataract Eye Surgeon at the Center for Excellence in Eye Care, Miami, FL.
Unraveling Refractory Dry Eye:
But here's where it gets controversial... Dr. Starr boldly asserts, "I don't believe in 'refractory dry eye.'" He emphasizes the treatability of all dry eye disease (DED) and ocular surface disease (OSD), highlighting the importance of thorough investigation and a comprehensive treatment approach.
Dr. Starr explains that when patients describe their dry eye as "refractory," it often indicates a misdiagnosis. In his practice, he finds that many such cases are actually neuropathic corneal pain syndrome, a condition often overlooked.
Dr. Trattler adds a practical perspective, suggesting a step-by-step approach for managing severe dry eye cases. He recommends starting with tear volume enhancement using canalicular gel (Lacrifill) and progressing to anti-inflammatory medications. Focusing on the eyelids with therapies like TearCare or LipiFlow can improve the lipid layer of the tear film. Additionally, the neuromodulator eye drop acoltremon (Tryptyr) may stimulate basal tear secretion.
Emerging Therapies: A Ray of Hope?
When it comes to new treatments, Dr. Starr is enthusiastic about FDA-approved medications with novel mechanisms of action. He highlights acoltremon (Tryptyr) and perfluorohexyloctane (Miebo) as recent approvals with great potential. Additionally, he expresses excitement about the upcoming approvals of unique medications like AZR-MD-001 for meibomian gland dysfunction and reproxolap.
But here's the part most people miss... Dr. Starr emphasizes the power of "self-biologics" - autologous serum drops. He praises Ocubio's recent entry into this field, providing patients with high-quality, standardized serum drops that don't require constant refrigeration.
The Role of Diagnostic Technology:
Diagnostic tools are a clinician's best friend, complementing a careful slit lamp exam. Dr. Starr shares his experience with osmolarity and MMP-9 testing, which have been integral to his DED/OSD workup. He expresses a desire for non-invasive tear break-up time (TBUT) testing and mentions the Brill non-contact esthesiometer as a valuable addition to his diagnostic toolkit, aiding in the early diagnosis of corneal DED masqueraders.
What's Next in Tear Film Monitoring?
Dr. Starr acknowledges that he's not aware of any imminent novel tear film imagers or diagnostic tests on the horizon. However, he leaves us with a thought-provoking question: Are we missing something?
As we navigate the complex world of dry eye management, these experts provide valuable insights into the evolving landscape of ophthalmology. Join the conversation and share your thoughts on these strategies and technologies. What do you think is the most promising development in dry eye treatment? Don't forget to leave your comments below!
